Entresto vs. Ranexa

• Are Entresto and Ranexa the Same Thing?
• What Are Possible Side Effects of Entresto?
• What Are Possible Side Effects of Ranexa?
• What Is Entresto?
• What Is Ranexa?
• What drugs interact with Entresto?
• What drugs interact with Ranexa?
• How Should Entresto Be Taken?
• How Should Ranexa Be Taken?

Entresto (sacubitril and valsartan) and Ranexa (ranolazine) are used to treat different kinds of heart problems.

Entresto is used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

Ranexa is prescribed to treat chronic angina.

Entresto and Ranexa belong to different drug classes. Entresto is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker (ARB) and Ranexa is an anti-anginal medication.

Side effects of Entresto and Ranexa that are similar include dizziness.

Side effects of Entresto that are different from Ranexa include low blood pressure (hypotension), high blood potassium (hyperkalemia), cough, and kidney (renal) failure.

Side effects of Ranexa that are different from Entresto include spinning sensation, nausea, vomiting, stomach pain, constipation, headache, dry mouth, weakness, ringing in your ears, swelling in hands/ankles/feet, slow/fast/irregular heartbeats, tremors, blood in the urine, and shortness of breath.

Entresto may interact with angiotensin-converting-enzyme (ACE) inhibitors, other angiotensin receptor blockers (ARBs), potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), or lithium.

Ranexa may interact with grapefruit and grapefruit juice, antibiotics, antifungals, other medicines to treat heart disease, cholesterol-lowering medicines, diabetes medications, medicines to prevent organ transplant rejection, medicines to treat mental illness, or medicines to treat or prevent nausea and vomiting caused by chemotherapy or radiation.

Side effects of Entresto include:

• low blood pressure (hypotension),
• high blood potassium (hyperkalemia),
• cough,
• dizziness, and
• kidney (renal) failure

Common side effects of Ranexa include:

• stomach upset,
• nausea,
• vomiting,
• flushing (warmth, redness, or tingly feeling),
• constipation,
• headache,
• confusion,
• memory problems,
• loss of balance or coordination,
• blurred vision,
• double vision,
• eye redness,
• lightheadedness,
• dizziness,
• spinning sensation,
• drowsiness,
• sleep problems (insomnia),
• stuffy nose,
• itching, or
• rash, especially during the first few days as your body adjusts to this medication.

Tell your doctor if you experience serious side effects of Ranexa including:

• fever,
• chills,
• flu symptoms,
• slow heart rate,
• feeling like you might pass out,
• seizures (convulsions), or
• jaundice (yellowing of your skin or eyes).

Entresto (sacubitril and valsartan) is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

Ranexa (methocarbamol) is a muscle relaxant used together with rest and physical therapy to treat skeletal muscle conditions such as pain or injury.

Entresto may interact with angiotensin-converting-enzyme (ACE) inhibitors, other angiotensin receptor blockers (ARBs), potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), or lithium. Tell your doctor all medications and supplements you use. Entresto is not recommended for use during pregnancy. It may harm a fetus. Entresto is not recommended for use while breastfeeding.

Ranexa may interact with other medicines that can make you sleepy or slow your breathing (such as cold or allergy medicines, narcotic pain medicines, sleeping pills, muscle relaxers, and medicines for depression, seizure, anxiety), and heart or blood pressure medications. Ranexa may also interact with carbamazepine, diazepam, fluoxetine, olanzapine, fluvoxamine, omeprazole, rifampin, or medications to treat Parkinson's disease.

Entresto (ziprasidone HCl) is available as capsules and Entresto (ziprasidone mesylate) is available as an injection for intramuscular use.

Entresto Capsules should be administered at an initial daily dose of 20 mg twice daily with food. For intramuscular dosing, the recommended dose of Entresto is 10 mg to 20 mg administered as required up to a maximum dose of 40 mg per day.

The recommended starting dose of Entresto is 49/51 mg twice-daily. Double the dose of Entresto after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice-daily, as tolerated by the patient.